A citation-based method for searching scientific literature

Bogdan-Dragos Grigoriu, Arnaud Scherpereel, Patrick Devos, Bachar Chahine, Marc Letourneux, Pierre Lebailly, Marc Grégoire, Henri Porte, Marie-Christine Copin, Philippe Lassalle. Clin Cancer Res 2007
Times Cited: 151







List of co-cited articles
952 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mesothelin-family proteins and diagnosis of mesothelioma.
Bruce W S Robinson, Jenette Creaney, Richard Lake, Anna Nowak, A William Musk, Nick de Klerk, Pernilla Winzell, Karl Erik Hellstrom, Ingegerd Hellstrom. Lancet 2003
400
51

Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
Harvey I Pass, Dan Lott, Fulvio Lonardo, Michael Harbut, Zhandong Liu, Naimei Tang, Michele Carbone, Craig Webb, Anil Wali. N Engl J Med 2005
279
50

Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Arnaud Scherpereel, Bogdan Grigoriu, Massimo Conti, Thomas Gey, Marc Grégoire, Marie-Christine Copin, Patrick Devos, Bachar Chahine, Henri Porte, Philippe Lassalle. Am J Respir Crit Care Med 2006
164
40

Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
Harvey I Pass, Stephen M Levin, Michael R Harbut, Jonathan Melamed, Luis Chiriboga, Jessica Donington, Margaret Huflejt, Michele Carbone, David Chia, Lee Goodglick,[...]. N Engl J Med 2012
183
38

Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.
Alfonso Cristaudo, Rudy Foddis, Agnese Vivaldi, Giovanni Guglielmi, Nicola Dipalma, Rosangela Filiberti, Monica Neri, Marcello Ceppi, Michela Paganuzzi, Gian Paolo Ivaldi,[...]. Clin Cancer Res 2007
113
36

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Jenette Creaney, Deborah Yeoman, Yvonne Demelker, Amanda Segal, A W Musk, Steven J Skates, Bruce W S Robinson. J Thorac Oncol 2008
79
45

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Harvey I Pass, Anil Wali, Naimei Tang, Alla Ivanova, Sergey Ivanov, Michael Harbut, Michele Carbone, Jeffrey Allard. Ann Thorac Surg 2008
102
31

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
Kevin Hollevoet, Kristiaan Nackaerts, Joël Thimpont, Paul Germonpré, Lionel Bosquée, Paul De Vuyst, Catherine Legrand, Eliane Kellen, Yoshiro Kishi, Joris R Delanghe,[...]. Am J Respir Crit Care Med 2010
73
41

Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Joachim Schneider, Hans Hoffmann, Hendrik Dienemann, Felix J F Herth, Michael Meister, Thomas Muley. J Thorac Oncol 2008
55
52

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet, Johannes B Reitsma, Jenette Creaney, Bogdan D Grigoriu, Bruce W Robinson, Arnaud Scherpereel, Alfonso Cristaudo, Harvey I Pass, Kristiaan Nackaerts, José A Rodríguez Portal,[...]. J Clin Oncol 2012
134
29

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
Jenette Creaney, Ian M Dick, Tarek M Meniawy, Su Lyn Leong, Justine S Leon, Yvonne Demelker, Amanda Segal, A W Bill Musk, Y C Gary Lee, Steven J Skates,[...]. Thorax 2014
87
33

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold,[...]. J Clin Oncol 2003
28

Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Jenette Creaney, Ivonne van Bruggen, Michelle Hof, Amanda Segal, Arthur W Musk, Nick de Klerk, Nora Horick, Steven J Skates, Bruce W S Robinson. Chest 2007
64
39

Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Kevin Hollevoet, Kristiaan Nackaerts, Robert Gosselin, Walter De Wever, Lionel Bosquée, Paul De Vuyst, Paul Germonpré, Eliane Kellen, Catherine Legrand, Yoshiro Kishi,[...]. J Thorac Oncol 2011
59
42

Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
Paul Wheatley-Price, Boming Yang, Demetris Patsios, Devalben Patel, Clement Ma, Wei Xu, Natasha Leighl, Ronald Feld, B C John Cho, Brenda O'Sullivan,[...]. J Clin Oncol 2010
69
34

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.
Jenette Creaney, Deborah Yeoman, Leanne K Naumoff, Michelle Hof, Amanda Segal, Arthur William Musk, Nicholas De Klerk, Nora Horick, Steven J Skates, Bruce W S Robinson. Thorax 2007
90
25

The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
Kevin Hollevoet, Kristiaan Nackaerts, Olivier Thas, Joël Thimpont, Paul Germonpré, Paul De Vuyst, Lionel Bosquée, Catherine Legrand, Eliane Kellen, Yoshiro Kishi,[...]. Chest 2012
35
65

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
José A Rodríguez Portal, Eulogio Rodríguez Becerra, David Rodríguez Rodríguez, Inmaculada Alfageme Michavila, Aida Quero Martínez, Carmen Diego Roza, Antonio León Jiménez, Isabel Isidro Montes, Pilar Cebollero Rivas. Cancer Epidemiol Biomarkers Prev 2009
44
50

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.
A Scherpereel, P Astoul, P Baas, T Berghmans, H Clayson, P de Vuyst, H Dienemann, F Galateau-Salle, C Hennequin, G Hillerdal,[...]. Eur Respir J 2010
359
22

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
Raffit Hassan, Alan T Remaley, Maureen L Sampson, Jingli Zhang, Derrick D Cox, James Pingpank, Richard Alexander, Mark Willingham, Ira Pastan, Masanori Onda. Clin Cancer Res 2006
190
22

MESOMARK: a potential test for malignant pleural mesothelioma.
Heather L Beyer, Ryan D Geschwindt, Curtis L Glover, Ly Tran, Ingegerd Hellstrom, Karl-Erik Hellstrom, M Craig Miller, Thorsten Verch, W Jeffrey Allard, Harvey I Pass,[...]. Clin Chem 2007
97
22

Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
Jenette Creaney, Roslyn J Francis, Ian M Dick, Arthur W Musk, Bruce W S Robinson, Michael J Byrne, Anna K Nowak. Clin Cancer Res 2011
74
29

Advances in malignant mesothelioma.
Bruce W S Robinson, Richard A Lake. N Engl J Med 2005
775
21

Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
Eun-Kee Park, Alessandra Sandrini, Deborah H Yates, Jenette Creaney, Bruce W Robinson, Paul S Thomas, Anthony R Johnson. Am J Respir Crit Care Med 2008
77
25

Malignant mesothelioma.
Bruce W S Robinson, Arthur W Musk, Richard A Lake. Lancet 2005
525
20


Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Kota Iwahori, Tadashi Osaki, Satoshi Serada, Minoru Fujimoto, Hidekazu Suzuki, Yoshiro Kishi, Akihito Yokoyama, Hironobu Hamada, Yoshihiro Fujii, Kentaro Yamaguchi,[...]. Lung Cancer 2008
39
48

Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
Monica Amati, Marco Tomasetti, Mario Scartozzi, Laura Mariotti, Renata Alleva, Elettra Pignotti, Battista Borghi, Matteo Valentino, Mario Governa, Jiri Neuzil,[...]. Cancer Epidemiol Biomarkers Prev 2008
44
40

Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
Bogdan D Grigoriu, Bachar Chahine, Anil Vachani, Thomas Gey, Massimo Conti, Daniel H Sterman, Genevieve Marchandise, Henri Porte, Steven M Albelda, Arnaud Scherpereel. Am J Respir Crit Care Med 2009
47
38

Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
Jenette Creaney, Nola J Olsen, Fraser Brims, Ian M Dick, Arthur W Musk, Nicholas H de Klerk, Steven J Skates, Bruce W S Robinson. Cancer Epidemiol Biomarkers Prev 2010
55
32


Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Alfonso Cristaudo, Alessandra Bonotti, Silvia Simonini, Agnese Vivaldi, Giovanni Guglielmi, Nicolino Ambrosino, Antonio Chella, Marco Lucchi, Alfredo Mussi, Rudy Foddis. J Thorac Oncol 2011
44
40

Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
Alex J Rai, Raja M Flores, Anu Mathew, Rita Gonzalez-Espinoza, Matthew Bott, Marc Ladanyi, Valerie Rusch, Martin Fleisher. Clin Chem Lab Med 2010
24
70

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
Jenette Creaney, Deborah Yeoman, Arthur William Musk, Nicholas de Klerk, Steven J Skates, Bruce W S Robinson. Lung Cancer 2011
37
45

Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Oluf Dimitri Roe, Jenette Creaney, Steinar Lundgren, Erik Larsson, Helmut Sandeck, Paolo Boffetta, Tom Ivar Nilsen, Bruce Robinson, Kristina Kjaerheim. Lung Cancer 2008
43
37

Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.
Rachel M Ostroff, Michael R Mehan, Alex Stewart, Deborah Ayers, Edward N Brody, Stephen A Williams, Stephen Levin, Brad Black, Michael Harbut, Michele Carbone,[...]. PLoS One 2012
91
17

Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
Masanori Onda, Satoshi Nagata, Mitchell Ho, Tapan K Bera, Raffit Hassan, Richard H Alexander, Ira Pastan. Clin Cancer Res 2006
83
18

Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.
Kazu Shiomi, Hideaki Miyamoto, Tatsuya Segawa, Yoshiaki Hagiwara, Akinobu Ota, Masahiro Maeda, Kazuhisa Takahashi, Kimihiko Masuda, Yukinori Sakao, Okio Hino. Cancer Sci 2006
61
22

Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
Bogdan Grigoriu, Bachar Chahine, Farid Zerimech, Marc Grégoire, Malika Balduyck, Marie-Christine Copin, Patrick Devos, Philippe Lassalle, Arnaud Scherpereel. Clin Biochem 2009
29
48

Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
Aliya N Husain, Thomas V Colby, Nelson G Ordóñez, Thomas Krausz, Alain Borczuk, Philip T Cagle, Lucian R Chirieac, Andrew Churg, Francoise Galateau-Salle, Allen R Gibbs,[...]. Arch Pathol Lab Med 2009
211
14

Mesothelin: a new target for immunotherapy.
Raffit Hassan, Tapan Bera, Ira Pastan. Clin Cancer Res 2004
326
14

Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
Alfonso Cristaudo, Rudy Foddis, Alessandra Bonotti, Silvia Simonini, Agnese Vivaldi, Giovanni Guglielmi, Nicolino Ambrosino, Pier Aldo Canessa, Antonio Chella, Marco Lucchi,[...]. Int J Biol Markers 2010
31
45

Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo, Huan-Zhong Shi, Qiu-Li Liang, Jing Jiang, Shou-Ming Qin, Jing-Min Deng. Respir Med 2010
43
30

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
Michaela B Kirschner, Emily Pulford, Mir Alireza Hoda, Anita Rozsas, Kim Griggs, Yuen Yee Cheng, J James B Edelman, Steven C Kao, Rebecca Hyland, Yawen Dong,[...]. Br J Cancer 2015
41
31

Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
Helen E Davies, Ross S Sadler, Silvia Bielsa, Nicholas A Maskell, Najib M Rahman, Robert J O Davies, Berne L Ferry, Y C Gary Lee. Am J Respir Crit Care Med 2009
71
16

Biomarkers for mesothelioma.
Arnaud Scherpereel, Y C Gary Lee. Curr Opin Pulm Med 2007
54
22

Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population.
Eun-Kee Park, Paul S Thomas, Jenette Creaney, Anthony R Johnson, Bruce W Robinson, Deborah H Yates. Clin Chem Lab Med 2010
22
54

Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.
Kevin Hollevoet, Joris Van Cleemput, Joël Thimpont, Paul De Vuyst, Lionel Bosquée, Kristiaan Nackaerts, Paul Germonpré, Stijn Vansteelandt, Yoshiro Kishi, Joris R Delanghe,[...]. J Thorac Oncol 2011
28
42

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice.
Mark Linch, Spyridon Gennatas, Stanislav Kazikin, Jhangir Iqbal, Ranga Gunapala, Kathryn Priest, Joanne Severn, Alison Norton, Bee Ayite, Jaishree Bhosle,[...]. BMC Cancer 2014
16
75

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Kazu Shiomi, Yoshiaki Hagiwara, Kouji Sonoue, Tatsuya Segawa, Kazuya Miyashita, Masahiro Maeda, Hiroshi Izumi, Kimihiko Masuda, Masataka Hirabayashi, Takao Moroboshi,[...]. Clin Cancer Res 2008
50
22


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.